ライフサイエンスコーパス: coronary lesion

1 coronary catheter with the tip distal to the coronary lesion.

2 ation (Hosmer-Lemeshow P=0.540) for an acute coronary lesion.

3 /=0.8 was regarded to indicate a significant coronary lesion.

4 gold standard for a hemodynamic significant coronary lesion.

5 nt interventional tool for heavily calcified coronary lesions.

6 vascular ultrasound-guided stenting of 1,015 coronary lesions.

7 e best method for interrogating intermediate coronary lesions.

8 tal stents (BMS) in the treatment of de novo coronary lesions.

9 trasound analysis was performed in 46 native coronary lesions.

10 stenosis after stent implantation in de novo coronary lesions.

11 ice-independent relationships seen in native coronary lesions.

12 he preferred treatment for heavily calcified coronary lesions.

13 nlargement commonly (54%) occurs at stenotic coronary lesions.

14 es, of functionally significant intermediate coronary lesions.

15 lanned stent implantation in de-novo, native coronary lesions.

16 curate in detecting functionally significant coronary lesions.

17 FFR was </=0.80 in 54 of 144 (38%) coronary lesions.

18 the gold standard for assessing intermediate coronary lesions.

19 tual histology IVUS and FFR for intermediate coronary lesions.

20 drug-eluting stents implantation in de novo coronary lesions.

21 ve, more targeted treatment of KD to prevent coronary lesions.

22 icient mice were protected from LCWE-induced coronary lesions.

23 simple and medium complexity single de novo coronary lesions.

24 ly identified necrotic core in ex vivo human coronary lesions.

25 vascular smooth muscle cells in the advanced coronary lesions.

26 t natural history trajectories of individual coronary lesions.

27 ding treatment of patients with intermediate coronary lesions.

28 tion fraction <40%), as well as more complex coronary lesions.

29 performed in 689 patients with 1,639 native coronary lesions.

30 tage of stenosis, and the development of new coronary lesions.

31 -IV trial, 1314 patients with single de novo coronary lesions 10 to 28 mm in length, with reference-v

32 A total of 1,314 patients with coronary lesions 10- to 28-mm long in 2.5- to 3.75-mm ve

33 bstudy enrolled 241 patients with 263 native coronary lesions (201 PES, 62 BMS) with baseline and 13-

34 y II included fewer left anterior descending coronary lesions (46.5% vs. 32.8%, p < 0.01), more type

35 Regression of human coronary lesions after 5 weeks of treatment with apoA-I(

36 on angioplasty was performed in 1,266 native coronary lesions alone (n = 541) or after extraction ath

37 rediction model for the presence of an acute coronary lesion among patients resuscitated from an arre

38 y should be favored in patients with complex coronary lesions and anatomy and PCI in less complicated

39 ogical significance of intermediate severity coronary lesions and cases with inadequate image quality

40 ts who underwent intervention of 2780 native coronary lesions and had complete high-quality preinterv

41 ure, minimum lumen diameter (MLD), number of coronary lesions and total occlusions were not significa

42 c patients or those with ischaemia-producing coronary lesions, and reduces ischaemia to a greater ext

43 sclerosis, BMI, as well as CRP and number of coronary lesions, are independently associated with acut

44 n of the disease through repeated use as new coronary lesions arise.

45 CFI was proportional to severity of the coronary lesion at baseline (r=0.63, P<0.0001) but not 6

46 antation in a broad cross section of de novo coronary lesions at 1 year are unknown.

47 We randomized 704 patients with bifurcation coronary lesions at 58 centers (30 from Europe and 28 fr

48 ne to concluding angiogram of all qualifying coronary lesions averaged for each patient.

49 e effective in reducing restenosis in simple coronary lesions, but the evidence base for contemporary

50 ned anatomic and hemodynamic assessment of a coronary lesion by a single noninvasive test.

51 hology and composition of culprit and stable coronary lesions by multidetector computed tomography (M

52 ention remodeling was assessed in 108 native coronary lesions by using intravascular ultrasound (IVUS

53 The mean number of coronary lesions causing 30% to 75% diameter stenosis wa

54 quent restenosis rates at 6 months in native coronary lesions (CAVEAT I, 50.8% for intimal resection

55 s the prediction of functionally significant coronary lesions compared with visual CTCA assessment bu

56 shed by clinical variables, they had greater coronary lesion complexity by American Heart Association

57 atus alone and for treatment by DM status by coronary lesion complexity.

58 Similar to human lesions, the coronary lesions contain macrophages, activated mDCs, an

59 ional registry of patients with intermediate coronary lesions, defined as 40% to 80% stenosis by angi

60 The management of intermediate coronary lesions, defined by a diameter stenosis of 40%

61 In total, 144 coronary lesions detected on CTCA were visually graded f

62 In the placebo group, new coronary lesions developed in 21 of 38 smokers and in 28

63 basis that the majority of these individual coronary lesions do not in fact go on to cause clinical

64 nonsubjective method to diagnose significant coronary lesions during MR stress testing.

65 ) with each other or against BMS for de novo coronary lesions, enrolling at least 100 patients and wi

66 accuracy for the detection of flow-limiting coronary lesions (FFR</=0.80) was compared with visual C

67 cium channel-blocking agents may prevent new coronary lesion formation, the progression of minimal le

68 n vascular and extravascular tissues promote coronary lesion formation.

69 We stained multiple coronary lesions from 24 randomly selected patients who

70 Sixty-seven stented coronary lesions from 59 patients who presented with ACS

71 ally colocalized to apoptotic VSMCs in human coronary lesions, further supporting a functional role f

72 ation (h2=0.51+/-0.17; P=0.001), and ectatic coronary lesions (h2=0.52+/-0.07; P=0.001).

73 Although effective coverage of challenging coronary lesions has warranted the use of overlapping dr

74 rasound imaging was used to study 212 native coronary lesions in 209 patients after percutaneous tran

75 .3 months) IVUS was used to study 251 native coronary lesions in 241 patients; 63 patients had treate

76 Thirty patients with at least 2 significant coronary lesions in different vessels were treated with

77 atomy and for early detection and grading of coronary lesions in non-diabetic patients.

78 t mice restored the ability of LCWE to cause coronary lesions in response to LCWE.

79 The development of coronary lesions in retransplanted isografts underlines

80 clerosis and prevents the development of new coronary lesions in smokers.

81 ta play critical roles in the development of coronary lesions in this KD mouse model, blocked by IL-1

82 liminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent

83 f WT and 100% of B cell(null) mice developed coronary lesions, indicating that T cells were required

84 When the culprit coronary lesion is distal to the right atrial (RA) branc

85 When the culprit coronary lesion is distal to the right atrial (RA) branc

86 might propose that stenting all intermediate coronary lesions is an appropriate solution.

87 lantation of the DREAMS 2G device in de-novo coronary lesions is feasible, with favourable safety and

88 n the era of drug-eluting stents for diffuse coronary lesions, IVUS-guided percutaneous coronary inte

89 A total of 1043 patients with focal de novo coronary lesions, <25 mm in length, in 2.5- to 4.0-mm ve

90 Coronary lesions may impair the transmission of pressure

91 Borderline coronary lesions might become functionally significant a

92 coronary stent deployment have more complex coronary lesion morphology and a more complicated clinic

93 g-Eluting Stents in the Treatment of De Novo Coronary Lesions [NEXT]; NCT01373502).

94 ntly from the development of significant new coronary lesions, not initially severe enough to cause i

95 rteritis that histopathologically mimics the coronary lesions observed in KD patients.

96 racoronary physiological evaluation of >/= 1 coronary lesion of intermediate severity between April 1

97 Coronary lesions of intermediate stenosis demonstrate si

98 mposition and macrophage infiltration in the coronary lesions of patients with diabetes mellitus.

99 32, p = 0.005) and minimum lumen diameter of coronary lesions (OR: 1.83, 95% CI: 1.01 to 3.55, p = 0.

100 subjects with the TT or CT genotype had >/=1 coronary lesion (P=0.001).

101 Coronary lesions predominantly arose in the first 2-3 cm

102 e myocardial jeopardy index, total number of coronary lesions, prior coronary revascularization, and

103 One or more coronary lesions progressed in 16 of 34 lovastatin-treat

104 al coronary events was positively related to coronary lesion progression for all three surrogate end

105 s compared with bare metal stents in de novo coronary lesions reduces major adverse cardiac events in

106 ed by the inability to identify intermediate coronary lesions responsible for ischemia.

107 Routine FFR assessment of coronary lesions safely changes management strategy in a

108 The assessment of functional coronary lesion severity using intracoronary physiologic

109 he Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) study.

110 Use of CCTA for physiological evaluation of coronary lesion-specific ischemia may facilitate evaluat

111 trial recruited patients with de novo native coronary lesions suitable for 1- or 2-vessel treatment w

112 lternative strategy that can target multiple coronary lesions suitable for treatment with any approve

113 er to discriminate high-risk versus low-risk coronary lesions than [(18)F]FDG.

114 o accelerated atherosclerosis, especially of coronary lesions that are susceptible to rupture.

115 ses were possible both of differences in the coronary lesions that developed in a normolipidemic as c

116 surgical treatment of significantly stenotic coronary lesions, the comprehensive and serial assessmen

117 inical trial involving patients with complex coronary lesions, the use of a sirolimus-eluting stent h

118 stratification of patients with intermediate coronary lesions to appropriate therapy.

119 Thirty-one patients with de novo native coronary lesions treated with DCA in the Serial Ultrasou

120 Physicians tended to assess coronary lesions treated with percutaneous coronary inte

121 trasound was used to study 25 de novo native coronary lesions treated with single MultiLink stents wi

122 p at 8.3 months) were performed in 15 native coronary lesions treated with the QuaDS-QP2 stent.

123 ing outcomes of patients with single de novo coronary lesions treated with ZES or PES.

124 S (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial.

125 In all significant coronary lesions two observers measured the degree of st

126 Eighty-four stable patients with isolated coronary lesions underwent coronary stent deployment sta

127 receptor antagonist prevented LCWE-mediated coronary lesions up to 3 days after LCWE injection.

128 risk stratified for the presence of an acute coronary lesion using 4 easily measured variables.

129 nsitivity but improved specificity for right coronary lesions using attenuation/scatter correction me

130 or the detection of functionally significant coronary lesions using fractional flow reserve (FFR) as

131 gle-arm trial evaluating outcomes in de novo coronary lesions visually estimated to be 10 to 28 mm in

132 The mean length of the coronary lesions was 32 mm.

133 The functional relevance of 133 coronary lesions was assessed by FFR in 54 patients with

134 timal cutoff values to predict flow-limiting coronary lesion were 10 mm for lesion length, 1.8 mm2 fo

135 All coronary lesions were 80% to 95% stenosis in severity.

136 IV trial, 1,314 patients with single de novo coronary lesions were assigned to implantation of the sl

137 Coronary lesions were classified as lesions with patholo

138 Before the introduction of DES, intermediate coronary lesions were commonly managed based on physiolo

139 Calcified coronary lesions were detected in all three image sets i

140 lysis also showed that CRP and the number of coronary lesions were independent predictors of risk of

141 Coronary lesions were induced in Yorkshire albino swine

142 Four groups of 5 balloon-induced coronary lesions were irradiated with 8, 12, 16, and 24

143 trial, in which 1,314 patients with de novo coronary lesions were randomized to either the paclitaxe

144 in 1,226 consecutive patients (1,259 native coronary lesions) who underwent a single vessel interven

145 g patients with stable angina and at least 1 coronary lesion with a fractional flow reserve </=0.80 w

146 Coronary lesions with a diameter narrowing >/=50% on vis

147 termined in normal and atherosclerotic human coronary lesions with a monoclonal antibody to human PLT

148 staining on the luminal endothelium of human coronary lesions with active monocyte entry.

149 nical interpretation of stenosis severity in coronary lesions with an independent assessment using qu

150 icient recipients had more severe aortic and coronary lesions with characteristic T cell infiltration

151 A consecutive series of 456 coronary lesions with in-stent restenosis was evaluated

152 In a subgroup of 210 patients, focal coronary lesions with mild luminal narrowing were identi

153 PCI of coronary lesions with reduced fractional flow reserve im

154 Obstructive coronary lesions with reduced luminal dimensions may res

155 utaneous revascularization of de novo native coronary lesions with reference vessel diameters between

156 atherosclerotic lesions, we studied 20 human coronary lesions with techniques that have previously be

157 rest according to the likelihood of an acute coronary lesion would have significant utility.